Ginsenoside Rh2 composition as well as preparation method and application thereof
Through the combination of oleic acid/linoleic acid and amphiphilic excipients, a high drug loading ginseng saponin Rh2 nano drug was prepared, which solved the problems of large particles and low bioavailability of traditional preparations, and achieved higher bioavailability and Effectiveness.
Patent Information
- Application Number
- CN202311826618.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-12-28
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2043-12-28
AI Technical Summary
It is difficult to effectively prepare high drug loading of ginseng saponin Rh2 nano drugs. Traditional preparations have problems such as large particles, insoluble in water and low bioavailability, which limits their clinical applications.
The nanosuspension of ginseng saponin Rh2 is prepared by combining oleic acid/linoleic acid and amphiphilic excipients (such as TPGS) through reduced pressure evaporation. The drug loading volume reaches 40%, and remains stable in gastrointestinal fluid. It is suitable for Oral and intravenous.
It significantly improves the bioavailability of ginseng saponin Rh2, improves the drug loading, and is simple in preparation, reduces the dosage of drugs and toxic side effects, and improves the efficacy.
Smart Images

Figure CN118903164A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of pharmaceutical preparations, and relates to a nano drug, and in particular to a nano-form high-drug-loading ginsenoside Rh2 composition, and a preparation method and application thereof. Background Art
[0002] Ginseng is a perennial herb with a sweet and slightly bitter taste and a warm and neutral nature. It has the effects of greatly replenishing vital energy, restoring pulse and strengthening deficiency, nourishing the spleen and lungs, promoting the production of body fluids, and calming the mind. Among the various chemical components of ginseng, such as saponins, amino acids and peptides, volatile oils, sugars, trace elements and other components, ginsenosides are one of the most important active ingredients.
[0003] Among them, ginsenoside Rh2 (G-Rh2) has been widely studied due to its outstanding anti-tumor activity. Compared with (20R)G-Rh2, (20S)G-Rh2 has a more outstanding anti-tumor effect, can directly kill tumor cells, inhibit tumor cell proliferation, induce tumor cell apoptosis, and has a significant effect on tumor cell metastasis and invasion. Studies have reported that G-Rh2 induces apoptosis of multiple types of cancer cells through multiple pathways to achieve an inhibitory effect on cancer cells; Chen et al. analyzed the results of microarrays and found that ginsenoside Rh2 inhibits liver cancer by regulating the differential expression of IncRNAs (long non-coding RNA) and mRNAs. In addition, ginsenoside Rh2 has a protective effect on myocardial damage, can enhance the body's immune function, and has anti-allergic, anti-asthmatic and other pharmacological effects. Its structure is as follows:
[0004]
[0005] Ginsenoside Rh2 is a secondary aglycone of ginseng with an extremely low content. It is now mostly obtained by degradation and transformation of ginsenosides with a higher content. Ginsenoside Rh2 mainly improves immune function, inhibits the occurrence, development and metastasis of tumors, induces tumor cell apoptosis and differentiation of cancer cells, changes the resistance of tumor cells to anticancer drugs and enhances the efficacy of anticancer drugs to give full play to its anti-tumor effect. It can also prevent or reduce certain toxic side effects caused by chemotherapy in commonly used cancer treatment methods.
[0006] A large number of basic and clinical studies have shown that ginsenoside Rh2 has broad application prospects in tumor treatment, but traditional preparations still have many problems, such as large particles, insolubility in water, low bioavailability, etc., which limit their clinical application. If we can improve the traditional preparation process and use modern technology to prepare new Chinese medicine containing ginsenosides, thereby improving its bioavailability, reducing drug dosage, reducing toxic side effects and improving efficacy, it will have important clinical significance. Summary of the invention
[0007] In view of this, the object of the present invention is to provide a ginsenoside Rh2 composition, which is a composition that can improve the oral bioavailability of ginsenoside Rh2.
[0008] It should be noted that ginsenoside Rh2 is a poorly soluble component and an active ingredient that has attracted much attention. However, unlike conventional poorly soluble drugs, the preparation of ginsenoside nanoparticles is extremely difficult. So far, the research on the nano drug delivery system of ginsenoside Rh2 is extremely limited, with only submicroemulsions, self-microemulsions, lipid nanoparticles (EPC, PLGA, DSPE-PEG as excipients, drug loading 7.2%), and nanoparticles prepared with chitosan and sodium tripolyphosphate as excipients with a drug loading of 7.89%; Rh2 micelles with PLGA-PEG as excipients, with a drug loading of <4% under the most optimized conditions.
[0009] There are relatively more studies on ginsenoside Rh2 liposomes. So far, the liposome with the highest drug loading is only 23%. The preparation of liposomes requires the use of a large amount of phospholipids, and the cost of phospholipids is high. At the same time, phospholipids have poor chemical stability and are easily oxidized during transportation and storage, which also has an adverse effect on the stability of the product. A series of measures taken to avoid or delay phospholipid oxidation will further increase the cost of the product. Therefore, in order to truly realize clinical applications, it is necessary to use more stable excipients to prepare Rh2 nanomedicines with higher drug loading.
[0010] Among all the nano drug delivery systems, nanosuspensions and nanocrystals have the highest drug loading, and the preparation of Rh2 nanocrystals or nanosuspensions seems to be a natural choice. However, ginsenoside Rh2 is quite special. The present invention tried various excipients as stabilizers to prepare Rh2 nanosuspensions by the most economical grinding method (top-down method), and set the drug-loading ratio at 1:2, but all of them failed without exception, either because the particle size was particularly large or because the stability was poor (irreversible precipitation and aggregation occurred when placed); later, the anti-solvent precipitation method was tried to screen for nanosuspensions that could prepare Rh2 nanoparticles and have good stability at a drug-loading ratio of 1:2, but the results were also unsuccessful. It shows that the conventional method and conventional excipients cannot successfully prepare Rh2 nanosuspensions, and another way is needed to obtain Rh2 nanocomposites with high drug loading.
[0011] In the early exploration process, the present invention unexpectedly found that after oleic acid was mixed into the ethanol solution of Rh2, TPGS was used as a stabilizer, and nanoparticles of ginsenoside Rh2 similar to nanosuspensions could be successfully prepared, which were stable when placed and in artificial gastrointestinal fluid, and had a drug loading of up to 40%. Replacing oleic acid with linoleic acid, and mixtures of oleic acid-linoleic acid in different proportions, still had excellent stability and high drug loading, but after replacing oleic acid with soybean oil, corn oil, and olive oil, stable Rh2 nanoparticles could not be successfully prepared, suggesting that oleic acid / linoleic acid may have a certain specific interaction with Rh2, which can help Rh2 complete assembly under the stabilizing effect of TPGS to form high-drug-loaded nanoparticles similar to nanosuspensions; and replacing TPGS with other amphiphilic excipients, it was found that Rh2 nanoparticles could basically be prepared.
[0012] In order to achieve the purpose of the present invention, the present invention adopts the following technical solutions based on a large amount of research:
[0013] The first technical purpose of the present invention is to provide a ginsenoside Rh2 composition, which comprises ginsenoside Rh2, oleic acid / linoleic acid, and amphiphilic excipients; wherein,
[0014] The weight ratio of ginsenoside Rh2, oleic acid / linoleic acid and amphiphilic excipient is 4:2-8:1-8.
[0015] Optionally, the composition includes pharmaceutically acceptable excipients, including excipients for adjusting osmotic pressure and pH, specifically including glucose, sodium chloride, phosphate buffer, and glycerol.
[0016] Furthermore, the oleic acid / linoleic acid is a mixture of oleic acid and linoleic acid in any proportion, and the amphiphilic excipient includes one or more combinations of TPGS, PLA-PEG, PLGA-PEG, PCL-PEG, DSPE-PEG, phospholipids, and sodium oleate.
[0017] It should be noted that the average particle size of the ginsenoside Rh2 composition is 50-1000nm. The presence of oleic acid / linoleic acid is essential for the formation of the ginsenoside Rh2 nanocomposition. The ginsenoside Rh2 composition can effectively solve the problem of ginsenoside Rh2 being difficult to dissolve and administer, and oral administration can significantly improve the bioavailability of ginsenoside Rh2. The addition of borneol to the composition can further improve the oral bioavailability.
[0018] Moreover, the ginsenoside Rh2 composition can basically maintain its original particle size in gastrointestinal fluid (particle size change <100nm), and can be orally administered in the form of nanoparticles; the particle size remains basically stable in physiological saline, PBS, and 5% glucose (particle size change <100nm), and can be administered intravenously in the form of nanoparticles.
[0019] The second technical purpose of the present invention is to provide a method for preparing the ginsenoside Rh2 composition as described above, the method comprising the following steps:
[0020] Ginsenoside Rh2, amphiphilic excipients, and oleic acid / linoleic acid are dissolved in an organic solvent to obtain a mixed solution; the mixed solution is added to water under stirring or ultrasound, and the organic solvent is removed by evaporation under reduced pressure to finally obtain the ginsenoside Rh2 composition.
[0021] Or, a method for preparing the ginsenoside Rh2 composition, the method comprising the following steps:
[0022] Ginsenoside Rh2, oleic acid / linoleic acid, and amphiphilic excipients are dissolved in an organic solvent to obtain a mixed solution; the mixed solution is added to an aqueous solution containing sodium oleate under stirring or ultrasound, and the organic solvent is removed by evaporation under reduced pressure to finally obtain the ginsenoside Rh2 composition.
[0023] Optionally, the organic solvent includes one or more combinations of ethanol, methanol, and acetone, the volume of water is 3-50 times the volume of the organic solvent, the stirring speed is 300-2000rpm, and the water bath ultrasonic power is 100-500W.
[0024] Optionally, after adding 1% mannitol to the aqueous dispersion system prepared by the method and mixing evenly, freeze-drying is performed to obtain a solid powder of the ginsenoside Rh2 composition, which is convenient for long-term storage.
[0025] Mannitol is added to the aqueous nano-dispersion system and then freeze-dried to obtain a solid powder of the composition, which can be packed into capsules for oral administration or packed into bags as a granule and mixed with water before use before administration.
[0026] The third technical purpose of the present invention is to provide an application of the ginsenoside Rh2 composition as described above in a pharmaceutical preparation.
[0027] The ginsenoside Rh2 composition disclosed in the present invention can be used as an active ingredient together with a pharmaceutically acceptable excipient to prepare a pharmaceutical composition, and the pharmaceutical composition can be prepared into various dosage forms by conventional methods in the field of preparation, such as tablets, powders, granules, pills, capsules, tinctures, oral liquids, ointments, creams, emulsions or patches, etc. Depending on the dosage form, the excipients used in the pharmaceutical composition are also different, and the commonly used excipients include diluents, excipients, fillers, binders, wetting agents, disintegrants, absorption promoters, surfactants, adsorption carriers, lubricants, emulsifiers, and osmotic pressure regulators.
[0028] Furthermore, the ginsenoside Rh2 nanocomposition disclosed in the present invention is used for the treatment and prevention of tumors.
[0029] Compared with the prior art, the present invention has the following beneficial effects:
[0030] The present invention dissolves ginsenoside Rh2, oleic acid / linoleic acid, and amphiphilic excipients in an appropriate amount of ethanol or other organic solvents that are miscible with water, adds the mixture to the aqueous phase under stirring or ultrasonic action, and then removes the organic solvent by evaporation under reduced pressure to obtain a nanocomposite with an average particle size of 50-1000 nm. The drug loading easily reaches 30%, and the drug loading of the optimized prescription is 39.6%, which can be directly administered orally or intravenously. The preparation process of the composition is simple, and the oral bioavailability of the composition in rats is increased by more than 2.5 times compared with the physical suspension of Rh2. After a small amount of borneol is added to the prescription, the bioavailability is increased to 5.1 times. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying creative work.
[0032] Figure 1 This is a graph showing the particle size of the Rh2 composition prepared in Example 2.
[0033] Figure 2 This is a graph showing the changes in particle size and particle size distribution of the Rh2 composition prepared in Example 2 after being placed at room temperature for one week.
[0034] Figure 3 This is a graph showing the particle size of the Rh2 composition prepared in Example 3.
[0035] Figure 4 This is a graph showing the changes in particle size and particle size distribution of the Rh2 composition prepared in Example 3 after being placed at room temperature for one week.
[0036] Figure 5 This is a graph showing the change in particle size of the Rh2 composition prepared in Example 3 when incubated in different physiological media at 37°C.
[0037] Figure 6 This is a morphological photograph of the Rh2 composition prepared in Example 3 under a transmission electron microscope.
[0038] Figure 7 This is a graph showing the particle size of the Rh2 composition prepared in Example 4.
[0039] Figure 8 This is a graph showing the changes in particle size and particle size distribution of the Rh2 composition prepared in Example 5 after being placed at room temperature for one week.
[0040] Fig. 9 This is a graph showing the particle size of the Rh2 composition prepared in Example 8.
[0041] Fig.10 This is a graph showing the change in particle size of the Rh2 composition prepared in Example 47 when incubated in different physiological media at 37°C.
[0042] Fig.11 This is a graph showing the changes in particle size and particle size distribution of the Rh2 composition prepared in Example 47 when placed at room temperature for two weeks. DETAILED DESCRIPTION
[0043] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0044] The word "embodiment" used here as an "exemplary" does not necessarily mean that any embodiment described is superior to or better than other embodiments. Unless otherwise specified, the performance index tests in the embodiments of this application are performed using conventional test methods in the art. It should be understood that the terms described in this application are only used to describe specific implementation methods and are not used to limit the content disclosed in this application.
[0045] Unless otherwise specified, the technical and scientific terms used in this document have the same meanings as commonly understood by ordinary technicians in the technical field to which this application belongs; other experimental methods and technical means not specifically specified in this application refer to experimental methods and technical means commonly used by ordinary technicians in this field.
[0046] In order to better illustrate the content of the present application, numerous specific details are provided in the specific examples below. It should be understood by those skilled in the art that the present application can also be implemented without certain specific details. In the embodiments, some methods, means, instruments, equipment, etc. well known to those skilled in the art are not described in detail in order to highlight the main purpose of the present application.
[0047] Under the premise of no conflict, the technical features disclosed in the embodiments of the present application can be combined arbitrarily, and the resulting technical solutions belong to the contents disclosed in the embodiments of the present application.
[0048] In order to better understand the present invention, the present invention is further specifically described below through the following examples, but it should not be understood as a limitation of the present invention. Some non-essential improvements and adjustments made by technicians in this field based on the above invention content are also considered to fall within the protection scope of the present invention.
[0049] Example 1 Rh2:OA:TPGS=2:1:2, Rh2=2 mg / mL, theoretical drug loading 40%
[0050] Method: 8 mg of Rh2, 4 mg of oleic acid OA, and 8 mg of TPGS were weighed and dissolved in 0.6 mL of ethanol, and then dripped into 4 mL of water under 100 W water bath ultrasound, and the ethanol was removed by reduced pressure evaporation at 45 °C.
[0051] Results: Average particle size (209.0±11.9) nm, PDI value 0.210±0.029
[0052] Example 2 Rh2:OA:TPGS=2:2:1, Rh2=2.5 mg / mL, theoretical drug loading 40%
[0053] Method: Weigh 10 mg of Rh2, 10 mg of oleic acid OA, and 5 mg of TPGS, dissolve in 0.5 mL of ethanol, drip into 4 ml of water under 250 W water bath ultrasound, and evaporate under reduced pressure at 45 °C to remove ethanol.
[0054] Results: Particle size (143.5±1.709) nm, PDI value 0.199±0.012
[0055] After being placed at room temperature for one week, the particle size and particle size distribution did not change significantly, indicating good storage stability.
[0056] Example 3 Rh2:OA:TPGS=2:2:1, Rh2=5 mg / mL, theoretical drug loading 40%
[0057] Method: Weigh 15 mg Rh2, 15 mg oleic acid, and 7.5 mg TPGS and dissolve them in 0.6 ml ethanol. Add them dropwise into 3 ml water under 250W water bath ultrasound, and remove the ethanol by reduced pressure evaporation at 45°C.
[0058] Results: The average particle size was (164.3±2.203) nm, the PDI value was 0.177±0.015, and the measured drug loading was 39.7%.
[0059] After being placed at room temperature for one week, the particle size and particle size distribution did not change significantly, indicating good storage stability.
[0060] Example 4 Rh2:OA:TPGS=2:2:1, Rh2=8 mg / mL, theoretical drug loading 40%
[0061] Method: Weigh 16 mg Rh2, 16 mg oleic acid, and 8 mg TPGS and dissolve them in 0.6 ml ethanol. Add them dropwise into 2 ml water under 250W water bath ultrasound, and remove the ethanol by evaporation under reduced pressure at 45°C.
[0062] Results: The average particle size was (244.3±5.776) nm, the PDI value was 0.148±0.024, the measured drug loading was 39.8%, and the particle size and particle size distribution did not change significantly after being placed at room temperature for one week, indicating good storage stability.
[0063] Example 5 Rh2:OA:TPGS=2:2:1, Rh2=12 mg / mL, theoretical drug loading 40%
[0064] Method: Weigh 24 mg Rh2, 24 mg oleic acid, and 12 mg TPGS and dissolve them in 0.6 ml ethanol. Add them dropwise into 2 ml water under 300 W ultrasound, and evaporate under reduced pressure at 45 °C to remove ethanol.
[0065] Results: The average particle size was (238.6±6.950) nm, the PDI value was 0.208±0.021, it was stable at room temperature, and the measured drug loading was 39.5%.
[0066] Study on stability in physiological media: The prepared ginsenoside Rh2 nanoparticles were mixed with equal volumes of 2×PBS (2 times the concentration of PBS), 1.8% NaCl solution, and 10% glucose solution, or mixed with 4 times the volume of artificial gastric fluid or artificial intestinal fluid, and incubated at 37°C. The particle size and particle size distribution were measured at specific time points to observe whether turbidity, aggregation or precipitation occurred.
[0067] The results showed that except for the increase in particle size in fetal bovine serum (FBS), the particle size was stable in physiological saline, PBS, 5% glucose, artificial gastric juice, and artificial intestinal juice, and was suitable for both intravenous and oral administration.
[0068] Transmission electron microscopy showed that the nanocomposite was spherical or irregularly round.
[0069] Example 6 Rh2:OA:TPGS=2:2:2, Rh2=15 mg / mL
[0070] Method: Weigh 30 mg Rh2, 30 mg oleic acid, and 30 mg TPGS and dissolve them in 0.6 ml ethanol. Add them dropwise into 2 ml water under 300 W ultrasound, and evaporate under reduced pressure at 45 °C to remove ethanol.
[0071] Results: Average particle size (471.8±13.13) nm, PDI value 0.423±0.057.
[0072] After homogenization at 1500 bar for 10 times, the average particle size was (93.51±4.576) nm and the PDI value was 0.169±0.062.
[0073] Example 7 Rh2:OA:TPGS=2:2:2, Rh2=20 mg / mL
[0074] Method: Weigh 40 mg Rh2, 40 mg oleic acid, and 40 mg TPGS and dissolve them in 0.6 ml ethanol. Add them dropwise into 2 ml water under 300 W ultrasound and evaporate under reduced pressure at 45 °C to remove the ethanol.
[0075] Results: Average particle size (536.1±10.15) nm, PDI value 0.399±0.038.
[0076] After homogenization at 1500 bar for 15 times, the average particle size was (123.03±4.354) nm and the PDI value was 0.192±0.078.
[0077] Example 8 Rh2:OA:TPGS=2:2:4, Rh2=10 mg / mL
[0078] Method: Weigh 40 mg Rh2, 40 mg oleic acid, and 80 mg TPGS and dissolve them in 0.8 ml ethanol. Add them dropwise into 4 ml water under 250 W ultrasound, and evaporate under reduced pressure at 45 ° C to remove ethanol.
[0079] Results: The average particle size was (238.6±8.5) nm, the PDI value was 0.179±0.038, and no visible changes were observed after being placed at room temperature for one week.
[0080] Example 9 Rh2:OA:TPGS=2:4:2, Rh2=5 mg / mL
[0081] Method: Weigh 40 mg Rh2, 80 mg oleic acid, and 40 mg TPGS and dissolve them in 0.8 ml ethanol. Add them dropwise into 8 ml water under 250 W ultrasound, and evaporate under reduced pressure at 45 ° C to remove ethanol.
[0082] Results: The average particle size was (247.7±7.2) nm, the PDI value was 0.192±0.057, and no visible changes were observed after being placed at room temperature for one week.
[0083] Example 10 Rh2:OA:TPGS=4:4:1, Rh2=5 mg / mL, methanol
[0084] Method: Weigh 40 mg Rh2, 40 mg oleic acid, and 10 mg TPGS and dissolve them in 0.8 ml methanol. Add them dropwise into 8 ml water under 250 W ultrasound, and evaporate under reduced pressure at 45 ° C to remove methanol.
[0085] Results: The average particle size was (286.8±9.5) nm, the PDI value was 0.242±0.096, and no visible changes were observed after being placed at room temperature for one week.
[0086] Example 11 Rh2:OA:TPGS=4:4:2, Rh2=5 mg / mL, acetone
[0087] Method: Weigh 20 mg Rh2, 20 mg oleic acid, and 10 mg TPGS and dissolve them in 0.6 ml acetone. Add them dropwise into 4 ml water under 250W water bath ultrasound, and remove the acetone by evaporation under reduced pressure at 45°C.
[0088] Results: The average particle size was (226.7±5.332) nm, the PDI value was 0.158±0.035, and there was no visible change after being placed at room temperature for one week.
[0089] Example 12 Rh2:LA:TPGS=4:4:2, Rh2=5 mg / mL, acetone, linoleic acid
[0090] Method: Weigh 20 mg Rh2, 20 mg linoleic acid LA, and 10 mg TPGS and dissolve them in 0.6 ml acetone. Add them dropwise into 4 ml water under 250W water bath ultrasound, and evaporate the acetone under reduced pressure at 45°C.
[0091] Results: The average particle size was (203.4±4.897) nm, the PDI value was 0.166±0.045, and there was no visible change after being placed at room temperature for one week.
[0092] Example 13 Rh2:LA:TPGS=4:4:2, Rh2=5 mg / mL, methanol, linoleic acid
[0093] Method: Weigh 20 mg Rh2, 20 mg linoleic acid LA, and 10 mg TPGS and dissolve them in 0.6 ml methanol. Add them dropwise into 4 ml water under 250W water bath ultrasound, and evaporate under reduced pressure at 45°C to remove methanol.
[0094] Results: The average particle size was (235.8±5.921) nm, the PDI value was 0.178±0.063, and there was no visible change after being placed at room temperature for one week.
[0095] Example 14 Rh2: oleic acid: TPGS: sodium oleate = 4:4:2:1, drug loading ratio 4:7, theoretical drug loading = 36.36% (Rh2 concentration is 5 mg / mL)
[0096] Method: Weigh 20 mg of ginsenoside Rh2 and 20 mg of oleic acid and dissolve them in 0.5 ml of ethanol. Weigh 10 mg of TPGS and 5 mg of sodium oleate and dissolve them in 4 ml of water as the aqueous phase. Add the organic phase dropwise into 4 ml of the aqueous phase under ultrasound, and remove the ethanol by rotary evaporation at 45 °C.
[0097] Results: The average particle size was (155.8±1.343) nm, the PDI value was 0.205±0.006, and the surface potential was -(52.3±2.11) mV.
[0098] Particle size stability during room temperature storage: The newly prepared ginsenoside Rh2 nanoparticles were placed at room temperature for 30 days, and samples were taken on the 0th, 7th, 14th, and 30th days to measure the particle size and particle size distribution, and carefully observed whether there was turbidity, aggregation, or precipitation. As a result, after being placed at room temperature for one month, the average particle size remained almost unchanged, and the PDI fluctuated slightly but the fluctuation range was very small, indicating that the prepared ginsenoside Rh2 nanoparticles had good stability when placed at room temperature.
[0099] Example 15 Rh2:OA:TPGS=2:1:2, Rh2=2 mg / mL, stirring
[0100] Method: 8 mg of Rh2, 4 mg of oleic acid OA, and 8 mg of TPGS were weighed and dissolved in 0.6 mL of ethanol, and then dripped into 4 mL of water under stirring at 300 rpm. The ethanol was removed by evaporation under reduced pressure at 45 °C, and high-pressure homogenization was performed at 1500 bar for 5 times.
[0101] Results: Average particle size (226.0±8.9) nm, PDI value 0.221±0.027.
[0102] Example 16 Rh2:OA:TPGS=2:2:1, Rh2=2.5 mg / mL, stirring
[0103] Method: Weigh 10 mg of Rh2, 10 mg of oleic acid OA, and 5 mg of TPGS and dissolve them in 0.5 mL of ethanol. Pour the mixture dropwise into 4 mL of water under stirring at 500 rpm, and evaporate the ethanol under reduced pressure at 45 °C.
[0104] Results: Particle size (190.1±1.002) nm, PDI value 0.178±0.011.
[0105] Example 17 Rh2:OA:TPGS=2:2:1, Rh2=5 mg / mL, stirring
[0106] Method: Weigh 15 mg Rh2, 15 mg oleic acid, and 7.5 mg TPGS and dissolve them in 0.6 ml ethanol. Add them dropwise into 3 ml water under stirring at 1000 rpm, and evaporate under reduced pressure at 45°C to remove ethanol.
[0107] Results: The average particle size was (171.2±1.891) nm, the PDI value was 0.186±0.018, and the measured drug loading was 39.3%.
[0108] Example 18 Rh2:OA:TPGS=2:2:1, Rh2=8 mg / mL, stirring
[0109] Method: Weigh 16 mg Rh2, 16 mg oleic acid, and 8 mg TPGS and dissolve them in 0.6 ml ethanol. Add them dropwise into 2 ml water under stirring at 1500 rpm, and evaporate under reduced pressure at 45°C to remove ethanol.
[0110] Results: The average particle size was (229.1±4.582) nm, the PDI value was 0.153±0.023, and the measured drug loading was 39.6%.
[0111] Example 19 Rh2:OA:TPGS=2:2:1, Rh2=12 mg / mL, stirring
[0112] Method: Weigh 24 mg Rh2, 24 mg oleic acid, and 12 mg TPGS and dissolve them in 0.6 ml ethanol. Add them dropwise into 2 ml water under stirring at 1800 rpm, and evaporate under reduced pressure at 45°C to remove ethanol.
[0113] Results: The average particle size was (241.7±6.214) nm, the PDI value was 0.213±0.019, and the measured drug loading was 39.2%.
[0114] Example 20 Rh2:OA:TPGS=2:2:2, Rh2=15 mg / mL, stirring
[0115] Method: Weigh 30 mg Rh2, 30 mg oleic acid, and 30 mg TPGS and dissolve them in 0.6 ml ethanol. Add them dropwise into 2 ml water under stirring at 2000 rpm. Ethanol is removed by evaporation under reduced pressure at 45°C and the particle size is measured.
[0116] Results: The average particle size was (538.8±12.49) nm, and the PDI value was 0.505±0.061. After homogenization at 1500 bar for 10 times, the average particle size was (106.43±3.869) nm, and the PDI value was 0.157±0.052.
[0117] Example 21 Rh2:OA:TPGS=2:2:2, Rh2=20 mg / mL, stirring
[0118] Method: Weigh 40 mg Rh2, 40 mg oleic acid, and 40 mg TPGS and dissolve them in 0.6 ml ethanol. Add them dropwise into 2 ml water under stirring at 2000 rpm, and evaporate under reduced pressure at 45°C to remove ethanol.
[0119] Results: The average particle size was (672.1±15.82) nm, and the PDI value was 0.471±0.074. After homogenization at 1500 bar for 15 times, the average particle size was (158.93±4.132) nm, and the PDI value was 0.201±0.067.
[0120] Example 22 Rh2:OA:TPGS=2:2:4, Rh2=10 mg / mL, stirring
[0121] Method: Weigh 40 mg Rh2, 40 mg oleic acid, and 80 mg TPGS and dissolve them in 0.8 ml ethanol. Add them dropwise into 4 ml water under stirring at 1600 rpm, and evaporate under reduced pressure at 45°C to remove ethanol.
[0122] Results: The average particle size was (241.6±6.4) nm, and the PDI value was 0.183±0.041.
[0123] Example 23 Rh2: oleic acid: TPGS: sodium oleate = 4:4:2:1, stirring
[0124] Method: Weigh 20 mg of ginsenoside Rh2 and 20 mg of oleic acid and dissolve them in 0.5 ml of ethanol. Weigh 10 mg of TPGS and 5 mg of sodium oleate and dissolve them in 4 ml of water as the aqueous phase. Add the organic phase dropwise into 4 ml of the aqueous phase under stirring at 1600 rpm, and remove the ethanol by evaporation under reduced pressure at 45°C.
[0125] Results: Average particle size (151.6±3.4) nm, PDI value 0.161±0.025.
[0126] Example 24 Rh2:LA:TPGS=2:1:2, Rh2=2 mg / mL, linoleic acid
[0127] Method: Weigh 8 mg of Rh2, 4 mg of linoleic acid LA, and 8 mg of TPGS and dissolve them in 0.6 mL of ethanol. Pour the mixture dropwise into 4 mL of water under stirring at 300 rpm, and evaporate the ethanol under reduced pressure at 45 °C.
[0128] Results: Average particle size (203.1±5.4) nm, PDI value 0.197±0.023
[0129] Example 25 Rh2:LA:TPGS=2:2:1, Rh2=2.5 mg / mL, linoleic acid
[0130] Method: Weigh 10 mg of Rh2, 10 mg of linoleic acid LA, and 5 mg of TPGS and dissolve them in 0.5 mL of ethanol. Pour the mixture dropwise into 4 mL of water under stirring at 500 rpm, and evaporate the ethanol under reduced pressure at 45 °C.
[0131] Results: Particle size (187.2±1.023) nm, PDI value 0.171±0.012
[0132] Example 26 Rh2:LA:TPGS=2:2:1, Rh2=5 mg / mL, linoleic acid
[0133] Method: Weigh 15 mg Rh2, 15 mg linoleic acid LA, and 7.5 mg TPGS and dissolve them in 0.6 ml ethanol. Add them dropwise into 3 ml water under stirring at 1000 rpm, and evaporate under reduced pressure at 45°C to remove the ethanol.
[0134] Results: The average particle size was (167.5±2.673) nm, the PDI value was 0.175±0.015, the measured drug loading was 39.5%, and no visible changes were observed after being placed at room temperature for one week.
[0135] Example 27 Rh2:LA:TPGS=2:2:1, Rh2=8 mg / mL, linoleic acid
[0136] Method: Weigh 16 mg Rh2, 16 mg linoleic acid LA, and 8 mg TPGS and dissolve them in 0.6 ml ethanol. Add them dropwise into 2 ml water under stirring at 1500 rpm, and evaporate under reduced pressure at 45°C to remove the ethanol.
[0137] Results: The average particle size was (207.6±3.893) nm, the PDI value was 0.161±0.031, the measured drug loading was 39.2%, and no visible changes were observed after being placed at room temperature for one week.
[0138] Example 28 Rh2:LA:TPGS=2:2:1, Rh2=12 mg / mL, linoleic acid
[0139] Method: Weigh 24 mg Rh2, 24 mg linoleic acid LA, and 12 mg TPGS and dissolve them in 0.6 ml ethanol. Add them dropwise into 2 ml water under stirring at 1800 rpm, and evaporate under reduced pressure at 45°C to remove the ethanol.
[0140] Results: The average particle size was (237.6±5.860) nm, the PDI value was 0.201±0.017, it was stable at room temperature, and the measured drug loading was 39.6%.
[0141] Example 29 Rh2:LA:TPGS=2:2:4, Rh2=10 mg / mL, linoleic acid
[0142] Method: Weigh 40 mg Rh2, 40 mg linoleic acid LA, and 80 mg TPGS and dissolve them in 0.8 ml ethanol. Add them dropwise into 4 ml water under 250W ultrasound, and evaporate under reduced pressure at 45°C to remove the ethanol.
[0143] Results: Average particle size (252.1±7.9) nm, PDI value 0.203±0.043.
[0144] Example 30 Rh2:LA:TPGS:sodium oleate=4:4:2:1, linoleic acid
[0145] Method: Weigh 20 mg of ginsenoside Rh2 and 20 mg of linoleic acid LA and dissolve them in 0.8 ml of ethanol. Weigh 10 mg of TPGS and 5 mg of sodium oleate and dissolve them in 4 ml of water as the aqueous phase. Add the organic phase dropwise into 4 ml of the aqueous phase under 250 W ultrasound, and remove the ethanol by rotary evaporation at 45 °C.
[0146] Results: The average particle size was (142.1±3.0) nm, the PDI value was 0.157±0.021, and no visible changes were observed after being placed at room temperature for one week.
[0147] Example 31 Rh2:LA:OA:TPGS=2:1:1:1, Rh2=8 mg / mL, oleic acid+linoleic acid
[0148] Method: Weigh 16 mg Rh2, 8 mg oleic acid OA, 8 mg linoleic acid LA, and 8 mg TPGS and dissolve them in 0.6 ml ethanol. Add them dropwise into 2 ml water under stirring at 1500 rpm, and evaporate under reduced pressure at 45°C to remove ethanol.
[0149] Results: The average particle size was (198.5±3.562) nm, the PDI value was 0.160±0.029, the measured drug loading was 39.7%, and no visible changes were observed after being placed at room temperature for one week.
[0150] Example 32 Rh2:OA:LA:TPGS=2:2:1, Rh2=12 mg / mL, oleic acid+linoleic acid
[0151] Method: Weigh 24 mg Rh2, 12 mg linoleic acid OA, 12 mg linoleic acid LA, and 12 mg TPGS and dissolve them in 0.6 ml ethanol. Add them dropwise into 2 ml water under 250 W ultrasound, and evaporate under reduced pressure at 45 ° C to remove ethanol.
[0152] Results: The average particle size was (218.9±5.769) nm, the PDI value was 0.196±0.015, the measured drug loading was 39.3%, and no visible changes were observed after being placed at room temperature for one week.
[0153] Example 33 Rh2:OA:LA:TPGS=2:2:4, Rh2=10 mg / mL, oleic acid + linoleic acid
[0154] Method: Weigh 40 mg Rh2, 20 mg oleic acid OA, 20 mg linoleic acid LA, and 80 mg TPGS and dissolve them in 0.8 ml ethanol. Add them dropwise into 4 ml water under 250W ultrasound, and evaporate under reduced pressure at 45°C to remove ethanol.
[0155] Results: The average particle size was (235.9±6.1) nm, the PDI value was 0.178±0.038, and no visible changes were observed after being placed at room temperature for one week.
[0156] Example 34 Rh2:OA:LA:TPGS:sodium oleate=4:2:2:2:1, oleic acid+linoleic acid
[0157] Method: Weigh 20 mg of ginsenoside Rh2, 10 mg of oleic acid OA, and 10 mg of linoleic acid LA, and dissolve them in 0.6 ml of ethanol. Weigh 10 mg of TPGS and 5 mg of sodium oleate and dissolve them in 4 ml of water as the aqueous phase. Add the organic phase dropwise into 4 ml of the aqueous phase under stirring at 1600 rpm, and remove the ethanol by rotary evaporation at 45°C.
[0158] Results: The average particle size was (160.8±3.6) nm, the PDI value was 0.170±0.029, and no visible changes were observed after being placed at room temperature for one week.
[0159] Example 35 Rh2:LA:OA:PLA2000-PEG2000=2:1:1:1, Rh2=8 mg / mL, oleic acid+linoleic acid, PLA-PEG
[0160] Method: Weigh 16 mg Rh2, 8 mg oleic acid OA, 8 mg linoleic acid LA, and 8 mg PLA2000-PEG2000, dissolve in 0.6 ml ethanol, add dropwise into 2 ml water under stirring at 1500 rpm, and evaporate under reduced pressure at 45°C to remove ethanol.
[0161] Results: The average particle size was (213.4±4.572) nm, the PDI value was 0.176±0.035, and there was no visible change after being placed at room temperature for one week.
[0162] Example 36 Rh2:OA:LA:PLA2000-PEG2000=2:2:1, Rh2=12 mg / mL, oleic acid+linoleic acid, PLA-PEG
[0163] Method: Weigh 24 mg Rh2, 12 mg linoleic acid OA, 12 mg linoleic acid LA, and 12 mg PLA2000-PEG2000, dissolve in 0.6 ml ethanol, add dropwise to 2 ml water under 250W ultrasound, and evaporate under reduced pressure at 45°C to remove ethanol.
[0164] Results: The average particle size was (226.9±6.231) nm, the PDI value was 0.208±0.018, the measured drug loading was 39.2%, and no visible changes were observed after being placed at room temperature for one week.
[0165] Example 37 Rh2:OA:PLGA2000-PEG2000=2:2:1, Rh2=8 mg / mL, oleic acid+linoleic acid, PLGA-PEG
[0166] Method: Weigh 16 mg Rh2, 16 mg oleic acid OA, and 8 mg PLGA2000-PEG2000, dissolve in 0.6 ml ethanol, add dropwise into 2 ml water under stirring at 1500 rpm, and evaporate under reduced pressure at 45°C to remove ethanol.
[0167] Results: The average particle size was (205.4±4.218) nm, the PDI value was 0.171±0.030, and there was no visible change after being placed at room temperature for one week.
[0168] Example 38 Rh2:LA:PLGA2000-PEG2000=2:2:1, Rh2=12 mg / mL, oleic acid+linoleic acid, PLGA-PEG
[0169] Method: Weigh 24 mg Rh2, 24 mg linoleic acid LA, and 12 mg PLGA2000-PEG2000, dissolve in 0.6 ml ethanol, add dropwise to 2 ml water under 250W ultrasound, and evaporate under reduced pressure at 45°C to remove ethanol.
[0170] Results: The average particle size was (216.7±5.8652) nm, the PDI value was 0.198±0.014, and there was no visible change after one week.
[0171] Example 39 Rh2:OA:DSPE-PEG2000=2:2:1, Rh2=8 mg / mL, oleic acid+linoleic acid, DSPE-PEG
[0172] Method: Weigh 16 mg Rh2, 16 mg oleic acid OA, and 8 mg DSPE-PEG2000 and dissolve them in 0.6 ml ethanol. Add them dropwise into 2 ml water under stirring at 1500 rpm, and evaporate under reduced pressure at 45°C to remove ethanol.
[0173] Results: The average particle size was (193.6±4.003) nm, the PDI value was 0.168±0.026, and there was no visible change after being placed at room temperature for one week.
[0174] Example 40 Rh2:LA:DSPE-PEG2000=2:2:1, Rh2=12 mg / mL, oleic acid+linoleic acid, PLGA-PEG
[0175] Method: Weigh 24 mg Rh2, 24 mg linoleic acid LA, and 12 mg DSPE-PEG2000, dissolve in 0.6 ml ethanol, add dropwise to 2 ml water under 250W ultrasound, and evaporate under reduced pressure at 45°C to remove ethanol.
[0176] Results: The average particle size was (203.5±5.003) nm, the PDI value was 0.187±0.019, and there was no visible change after being placed at room temperature for one week.
[0177] Example 41 Rh2:OA:TPGS:DSPE-PEG2000=4:4:1:1, Rh2=8 mg / mL, TPGS+DSPE-PEG
[0178] Method: Weigh 16 mg Rh2, 16 mg oleic acid OA, 4 mg TPGS, and 4 mg DSPE-PEG2000 and dissolve them in 0.6 ml ethanol. Add them dropwise into 2 ml water under stirring at 1500 rpm, and evaporate under reduced pressure at 45°C to remove ethanol.
[0179] Results: The average particle size was (211.6±6.329) nm, the PDI value was 0.175±0.032, and there was no visible change after being placed at room temperature for one week.
[0180] Example 42 Rh2:LA:TPGS:PLA2000-PEG2000=4:4:1:1, TPGS+PLA-PEG
[0181] Method: Weigh 16 mg Rh2, 16 mg linoleic acid LA, 4 mg TPGS, and 4 mg PLA2000-PEG2000 and dissolve them in 0.6 ml ethanol. Add them dropwise into 4 ml water under 250W water bath ultrasound, and remove the ethanol by reduced pressure evaporation at 45°C.
[0182] Results: The average particle size was (198.2±5.294) nm, the PDI value was 0.173±0.033, and there was no visible change after being placed at room temperature for one week.
[0183] Example 43 Rh2:LA:OA:PCL2000-PEG2000:PLA1000-PEG2000=4:2:2:1:1, PCL-PEG+PLA-PEG
[0184] Method: Weigh 16 mg Rh2, 8 mg oleic acid OA, 8 mg linoleic acid LA, 4 mg PCL2000-PEG2000, and 4 mg PLA1000-PEG2000, dissolve in 0.6 ml ethanol, add dropwise to 4 ml water under 250W water bath ultrasound, and evaporate under reduced pressure at 45°C to remove ethanol.
[0185] Results: The average particle size was (214.8±6.025) nm, the PDI value was 0.183±0.040, and there was no visible change after being placed at room temperature for one week.
[0186] Example 44 Rh2:OA:SPC, SPC
[0187] Method: Weigh 16 mg Rh2, 16 mg oleic acid OA, and 8 mg soybean lecithin SPC and dissolve them in 0.6 ml ethanol. Add them dropwise into 4 ml water under 250W water bath ultrasound, and remove the ethanol by reduced pressure evaporation at 45°C.
[0188] Results: Average particle size (205.7±8.425) nm, PDI value 0.191±0.051.
[0189] Example 45 Rh2: linoleic acid: EPC, EPC
[0190] Method: Weigh 16 mg Rh2, 16 mg linoleic acid LA, and 8 mg egg yolk phosphatidylcholine EPC and dissolve them in 0.6 ml ethanol. Add them dropwise into 4 ml water under 250W water bath ultrasound, and remove the ethanol by reduced pressure evaporation at 45°C.
[0191] Results: Average particle size (183.7±6.429) nm, PDI value 0.182±0.043.
[0192] Example 46 Rh2: linoleic acid: DSPC, DSPC
[0193] Method: Weigh 16 mg Rh2, 16 mg linoleic acid LA, and 8 mg DSPC and dissolve them in 0.6 ml ethanol. Add them dropwise into 4 ml water under 250W water bath ultrasound, and evaporate under reduced pressure at 45°C to remove the ethanol.
[0194] Results: Average particle size (196.1±6.032) nm, PDI value 0.171±0.032.
[0195] Example 47 Rh2:LA:Borneol:TPGS
[0196] Method: Weigh 12 mg Rh2, 13 mg linoleic acid LA, 5 mg borneol, and 7.5 mg TPGS and dissolve them in 0.6 ml ethanol. Add them dropwise into 3 ml water under 250W water bath ultrasound, and evaporate under reduced pressure at 45°C to remove ethanol.
[0197] Results: The average particle size was (164.3±2.203) nm, the PDI value was 0.177±0.015, and no visible changes were observed after two weeks at room temperature, and no significant changes were observed in the particle size and particle size distribution (see Fig.11 ).
[0198] Particle size stability in physiological media: e.g. Fig.10 As shown, during the 12-hour incubation period, the Rh2 composition had no visible turbidity, aggregation or precipitation at all time points, and the particle size in glucose, artificial gastrointestinal fluid, artificial intestinal fluid, PBS, and FBS remained almost unchanged, indicating that it was stable in these physiological media. Therefore, the prepared ginsenoside Rh2 nanoparticles can be directly administered orally, and can be dispersed in 5% glucose or PBS for injection. During the incubation process in physiological saline, the particle size increased to more than 2000nm, indicating that the stability in physiological saline was poor, and physiological saline should be avoided as a dispersion medium for injection.
[0199] Example 48 Rh2:OA:TPGS=2:2:1, ethanol-acetone (volume ratio 1:1) as the organic phase
[0200] Method: Weigh 16 mg Rh2, 16 mg oleic acid, and 8 mg TPGS and dissolve them in 0.6 ml ethanol-acetone mixture (volume ratio 1:1), add them dropwise into 2 ml water under 250W water bath ultrasound, and evaporate under reduced pressure at 45°C to remove ethanol.
[0201] Results: The average particle size was (223.5±5.801) nm, the PDI value was 0.153±0.031, and the particle size and particle size distribution did not change significantly after being placed at room temperature for one week, indicating good storage stability.
[0202] Example 49 Rh2:LA:TPGS=2:2:1, methanol-acetone (volume ratio 1:1) as the organic phase
[0203] Method: Weigh 16 mg Rh2, 16 mg linoleic acid, and 8 mg TPGS and dissolve them in 0.6 ml methanol-acetone mixture (volume ratio 1:1), add them dropwise into 2 ml water under 250W water bath ultrasound, and evaporate under reduced pressure at 45°C to remove ethanol.
[0204] Results: The average particle size was (253.8±6.013) nm, the PDI value was 0.163±0.033, and the particle size and particle size distribution did not change significantly after being placed at room temperature for one week, indicating good storage stability.
[0205] In order to further demonstrate the beneficial effects of the present invention and to better understand the present invention, the following comparative examples are used to further illustrate the technical features disclosed in the present invention, but they should not be construed as limiting the present invention. Other improvements made by those skilled in the art based on the above invention content without inventive work are also considered to fall within the scope of protection of the present invention.
[0206] Comparative Example 1 Rh2:OA=1:1, Rh2=2.5 mg / mL
[0207] Method: Weigh 10 mg of Rh2 and 10 mg of oleic acid OA, dissolve in 0.5 mL of ethanol, drip into 4 ml of water under stirring at 1000 rpm, and evaporate under reduced pressure at 45°C to remove ethanol.
[0208] Results: A lot of turbidity appeared immediately after the injection, and a lot of precipitation appeared after the ethanol was removed.
[0209] Comparative Example 2 Rh2:TPGS=1:1, Rh2=2.5 mg / mL
[0210] Method: Weigh 10 mg of Rh2 and 10 mg of TPGS and dissolve them in 0.5 mL of ethanol. Pour the mixture dropwise into 4 mL of water under stirring at 1000 rpm, and evaporate the ethanol under reduced pressure at 45 °C.
[0211] Results: Turbidity appeared immediately after injection, and aggregated precipitation occurred after the ethanol was removed.
[0212] Comparative Example 3 Rh2:TPGS=1:5, Rh2=2.5 mg / mL
[0213] Method: Weigh 10 mg of Rh2 and 50 mg of TPGS and dissolve them in 0.5 mL of ethanol. Pour the mixture dropwise into 4 mL of water under stirring at 1000 rpm and evaporate the ethanol under reduced pressure at 45 °C.
[0214] Results: Average particle size (353.7±12.6) nm, PDI value 0.379±0.086. However, irreversible precipitation occurred after overnight storage.
[0215] Comparative Example 4 Rh2:PLGA2000-PEG2000=1:3, Rh2=5 mg / mL
[0216] Method: Weigh 10 mg of Rh2 and 30 mg of PLGA2000-PEG2000, dissolve in 0.5 mL of ethanol, drip into 4 ml of water under stirring at 1000 rpm, and evaporate under reduced pressure at 45°C to remove ethanol.
[0217] Results: Turbidity appeared immediately after injection, and aggregated precipitation occurred after the ethanol was removed.
[0218] Comparative Example 5 Rh2:PCL2000-PEG2000=1:3, Rh2=5 mg / mL
[0219] Method: Weigh 10 mg of Rh2 and 30 mg of PCL2000-PEG2000 and dissolve them in 0.5 mL of ethanol. Pour the mixture dropwise into 4 mL of water under stirring at 1000 rpm, and evaporate the ethanol under reduced pressure at 45 °C.
[0220] Results: Turbidity appeared immediately after injection, and aggregated precipitation occurred after the ethanol was removed.
[0221] Comparative Example 6 Rh2:DSPE-mPEG2000=1:3, Rh2=5 mg / mL
[0222] Method: Weigh 10 mg of Rh2 and 30 mg of DSPE-PEG2000, dissolve in 0.5 mL of ethanol, drip into 4 ml of water under stirring at 1000 rpm, and evaporate under reduced pressure at 45°C to remove ethanol.
[0223] Results: Turbidity appeared immediately after injection, and aggregated precipitation occurred after the ethanol was removed.
[0224] Comparative Example 7 Rh2:P188=1:3, Rh2=5 mg / mL
[0225] Method: Weigh 10 mg of Rh2 and 30 mg of P188 and dissolve them in 0.5 mL of ethanol. Pour the mixture dropwise into 4 mL of water under stirring at 1000 rpm and evaporate the ethanol under reduced pressure at 45 °C.
[0226] Results: A lot of turbidity appeared immediately after the injection, and a lot of precipitation appeared after the ethanol was removed.
[0227] Comparative Example 8 Rh2:DSPE-mPEG2000=1:3, Rh2=5 mg / mL
[0228] Method: Weigh 10 mg of Rh2 and 30 mg of DSPE-PEG2000, dissolve in 0.5 mL of ethanol, drip into 4 ml of water under stirring at 1000 rpm, and evaporate under reduced pressure at 45°C to remove ethanol.
[0229] Results: Turbidity appeared immediately after injection, and aggregated precipitation occurred after the ethanol was removed.
[0230] Comparative Example 9 Rh2:SDS=1:3, Rh2=5 mg / mL
[0231] Method: Weigh 10 mg of Rh2 and 30 mg of sodium dodecyl sulfate SDS and dissolve them in 0.5 mL of ethanol. Pour the mixture dropwise into 4 mL of water under stirring at 1000 rpm and evaporate the ethanol under reduced pressure at 45 °C.
[0232] Results: A lot of turbidity appeared immediately after the injection, and a lot of precipitation appeared after the ethanol was removed.
[0233] Comparative Example 10 Rh2:SPC=1:3, Rh2=5 mg / mL
[0234] Method: Weigh 10 mg of Rh2 and 30 mg of soybean lecithin SPC and dissolve them in 0.5 mL of ethanol. Pour the mixture dropwise into 4 mL of water under stirring at 1000 rpm and evaporate the ethanol under reduced pressure at 45 °C.
[0235] Results: A lot of turbidity appeared immediately after the injection, and a lot of precipitation appeared after the ethanol was removed.
[0236] Comparative Example 11 Rh2:EPC=1:3, Rh2=5 mg / mL
[0237] Method: Weigh 10 mg of Rh2 and 30 mg of egg yolk phosphatidylcholine EPC and dissolve them in 0.5 mL of ethanol. Pour the mixture dropwise into 4 mL of water under stirring at 1000 rpm and evaporate the ethanol under reduced pressure at 45 °C.
[0238] Results: A lot of turbidity appeared immediately after the injection, and a lot of precipitation appeared after the ethanol was removed.
[0239] Comparative Example 12 Rh2: refined soybean oil: TPGS = 2:2:1, Rh2 = 2.5 mg / mL, soybean oil
[0240] Method: Weigh 10 mg of Rh2, 10 mg of refined soybean oil, and 5 mg of TPGS and dissolve them in 0.5 mL of ethanol. Pour the mixture dropwise into 4 mL of water under stirring at 500 rpm, and evaporate the ethanol under reduced pressure at 45 °C.
[0241] Results: Turbidity appeared immediately after injection, and aggregated precipitation occurred after the ethanol was removed.
[0242] Comparative Example 13 Rh2: refined soybean oil: TPGS = 2:2:1, Rh2 = 5 mg / mL, soybean oil
[0243] Method: Weigh 15 mg Rh2, 15 mg refined soybean oil, and 7.5 mg TPGS and dissolve them in 0.6 ml ethanol. Add them dropwise into 3 ml water under stirring at 1000 rpm. Ethanol is removed by evaporation under reduced pressure at 45°C and the particle size is measured.
[0244] Results: Turbidity appeared upon injection and aggregation and precipitation occurred after the ethanol was removed.
[0245] Comparative Example 14 Rh2: refined soybean oil: TPGS: sodium oleate = 4:4:2:1, soybean oil
[0246] Method: Weigh 20 mg of ginsenoside Rh2 and 10 mg of refined soybean oil and dissolve them in 0.6 ml of ethanol. Weigh 10 mg of TPGS and 5 mg of sodium oleate and dissolve them in 4 mL of water. Add the ethanol solution dropwise into the aqueous phase under 250 W ultrasound, and remove the ethanol by rotary evaporation at 45 °C.
[0247] Results: Turbidity appeared immediately after injection, and aggregated precipitation occurred after the ethanol was removed.
[0248] Comparative Example 15 Rh2: corn oil: TPGS = 2:2:1, Rh2 = 2.5 mg / mL, corn oil
[0249] Method: Weigh 10 mg of Rh2, 10 mg of corn oil, and 5 mg of TPGS and dissolve them in 0.5 mL of ethanol. Pour the mixture dropwise into 4 mL of water under stirring at 500 rpm, and evaporate the ethanol under reduced pressure at 45 °C.
[0250] Results: Turbidity appeared immediately after injection, and aggregated precipitation occurred after the ethanol was removed.
[0251] Comparative Example 16 Rh2: corn oil: TPGS = 2:2:1, Rh2 = 5 mg / mL, corn oil
[0252] Method: Weigh 15 mg Rh2, 15 mg corn oil, and 7.5 mg TPGS and dissolve them in 0.6 ml ethanol. Add them dropwise into 3 ml water under stirring at 1000 rpm, and evaporate under reduced pressure at 45°C to remove the ethanol.
[0253] Results: Turbidity appeared upon injection and aggregation and precipitation occurred after the ethanol was removed.
[0254] Comparative Example 17 Rh2: corn oil: TPGS: sodium oleate = 4:4:2:1, corn oil
[0255] Method: Weigh 20 mg of ginsenoside Rh2 and 10 mg of corn oil and dissolve them in 0.6 ml of ethanol. Weigh 10 mg of TPGS and 5 mg of sodium oleate and dissolve them in 4 ml of water as the aqueous phase. Add the organic phase dropwise into 4 ml of the aqueous phase under stirring at 1500 rpm, and remove the ethanol by rotary evaporation at 45 °C.
[0256] Results: Turbidity appeared immediately after injection, and aggregated precipitation occurred after the ethanol was removed.
[0257] Comparative Example 18 Rh2: olive oil: TPGS = 2:2:1, Rh2 = 2.5 mg / mL, olive oil
[0258] Method: Weigh 10 mg of Rh2, 10 mg of olive oil, and 5 mg of TPGS and dissolve them in 0.5 mL of ethanol. Pour the mixture dropwise into 4 mL of water under stirring at 500 rpm, and evaporate the ethanol under reduced pressure at 45 °C.
[0259] Results: Turbidity appeared immediately after injection, and aggregated precipitation occurred after the ethanol was removed.
[0260] Comparative Example 19 Rh2: olive oil: TPGS = 2:2:1, Rh2 = 5 mg / mL, olive oil
[0261] Method: Weigh 15 mg Rh2, 15 mg corn oil, and 7.5 mg TPGS and dissolve them in 0.6 ml ethanol. Add them dropwise into 3 ml water under stirring at 1000 rpm, and evaporate under reduced pressure at 45°C to remove the ethanol.
[0262] Results: Turbidity appeared upon injection and aggregation and precipitation occurred after the ethanol was removed.
[0263] Comparative Example 20 Rh2: olive oil: TPGS: sodium oleate = 4:4:2:1, olive oil
[0264] Method: Weigh 20 mg of ginsenoside Rh2 and 10 mg of olive oil and dissolve them in 0.6 ml of ethanol. Weigh 10 mg of TPGS and 5 mg of sodium oleate and dissolve them in 4 ml of water as the aqueous phase. Add the organic phase dropwise into 4 ml of the aqueous phase under stirring at 1500 rpm, and remove the ethanol by rotary evaporation at 45°C.
[0265] Results: Turbidity appeared immediately after injection, and aggregated precipitation occurred after the ethanol was removed.
[0266] Experimental Example 1 Investigation of Physiological Medium Particle Size Stability:
[0267] The prepared ginsenoside Rh2 nanoparticles were mixed with 2×PBS (2 times the concentration of PBS), 1.8% NaCl solution, 10% glucose solution, or mixed with 4 times the volume of artificial stomach and artificial intestinal fluid, incubated at 37°C, and the particle size and particle size distribution were measured at specific time points to observe whether turbidity, aggregation or precipitation occurred. Specific data and results are shown in the corresponding examples.
[0268] Experimental Example 2 Study on stability at room temperature:
[0269] The newly prepared ginsenoside Rh2 nanoparticles were placed at room temperature for 30 days, and samples were taken at different time points (such as 0, 7, 14, 30 days, or within a week) to measure the particle size and particle size distribution, and at the same time, carefully observed whether turbidity, aggregation or precipitation occurred. Specific data and results are shown in the corresponding examples.
[0270] Experimental Example 3 HPLC content determination method of ginsenoside Rh2:
[0271] Chromatographic conditions: the chromatographic column was C18 column (4.6 mm × 250 mm, 5 μm), the mobile phase was acetonitrile-water (63:37), the flow rate was 1.0 mL / min, the injection volume was 20 uL, the detection wavelength was 203 nm, and the column temperature was 25 °C.
[0272] Establishment of Rh2 standard curve: accurately weigh a certain amount of Rh2 in a volumetric flask, add an appropriate amount of chromatographic methanol, sonicate to fully dissolve the drug, dilute to volume with chromatographic methanol, shake well, and obtain a mother solution with a concentration of 1 mg / mL. Take the above mother solution and dilute it with chromatographic methanol to a series of standard solutions with concentrations of 0.5, 1, 2, 5, 10, 25, 50, 100, 200, and 500 μg / mL. Perform HPLC injection detection, and perform linear regression on the peak area (Y) and the drug concentration (X). The standard curve equation y=0.1299x-0.0992, R 2 =0.9992, and the linear range is 5-500 μg / mL.
[0273] Experimental Example 4 Determination of drug loading of ginsenoside Rh2 nanocomposition (nanoparticles similar to nanosuspension):
[0274] Take the freshly prepared Rh2 nanocomposite, freeze-dry it directly without adding any protective agent, accurately weigh 10 mg (denoted as W) of the freeze-dried powder into a 10 mL volumetric flask, add chromatographic methanol to dissolve and dilute to the mark and shake well. Accurately draw 1 mL from it into another 10 mL volumetric flask, add chromatographic methanol to dissolve and dilute to the mark and shake well.
[0275] Take 1 mL of the diluted solution (dilute with chromatographic methanol if necessary) into a HPLC sample bottle, perform HPLC analysis according to the chromatographic conditions in Experimental Example 3, record the peak area, and substitute the obtained peak area into the regression equation y = 0.1299x-0.0992 to calculate the drug concentration. Calculate the concentration C (mg / mL) of Rh2 in the first volumetric flask according to the dilution multiple, then the drug loading content of ginsenoside Rh2 in the nanocomposite (drug loading content) = 10C / W×100%.
[0276] Experimental Example 5: Lyophilization and reconstitution and screening of lyophilization protective agents:
[0277] The newly prepared ginsenoside Rh2 nanoparticles (Example 3) were freeze-dried after adding nothing, 1% trehalose, 1% glucose, and 1% mannitol. The freeze-dried powder was added with an equal volume of pure water and shaken. The particle size and particle size distribution after reconstitution were measured. The results are shown in the following table, indicating that mannitol is an excellent freeze-drying protective agent for ginsenoside Rh2 nanocompositions. The freeze-dried powder of Example 3 after adding 1% mannitol was reconstituted in PBS with a particle size of (140.4±2.67) nm and a PDI of 0.251±0.108.
[0278] Table 1 Screening of lyophilization protective agents in Example 3 (particle size and PDI of different lyophilization protective agents added)
[0279]
[0280] The Rh2 nanocomposition obtained in other examples was added with 1% mannitol and then freeze-dried. The freeze-dried powder was reconstituted by adding water and shaking. The results are shown in Table 2, which shows that mannitol has a good freeze-drying protection effect.
[0281] Table 2 Particle size and PDI of samples of different examples 3 after adding 1% mannitol and re-dissolving
[0282]
[0283] Experimental Example 6 Establishment of LC-MS / MS analysis method for Rh2 in rat plasma samples
[0284] Preparation of reference solution: Accurately weigh an appropriate amount of ginsenoside Rh2 standard, prepare a 5 mg / mL mother solution with chromatographic methanol and DMSO, dilute with methanol to a 50 μg / mL stock solution, and dilute with 50% methanol solution to prepare a series of standard solutions with concentrations of 10 ug / mL, 5 ug / mL, 2 ug / mL, 1 ug / ml, 500 ng / mL, 200 ng / mL, 100 ng / mL, 50 ng / mL, 20 ng / mL, 10 ng / mL, 5 ng / mL, 2 ng / mL, 1 ng / mL, and store at -20 degrees Celsius for future use. Accurately weigh an appropriate amount of nimodipine (IS), prepare a 50 μg / mL stock solution with methanol, prepare a 100 ng / mL single standard solution with 50% methanol, and store at -20 degrees Celsius for future use.
[0285] Preparation and treatment of standard samples: Take blank plasma from three SD rats that have fasted for 18 hours. Accurately draw 45μL of blank plasma, add 5uL of 1ng / mL-10ug / mL Rh2 standard solution, add 450μL of methanol and acetonitrile (1:1) precipitation solution, vortex at 2500speed for 5min, centrifuge at 13000rpm for 10min, draw 450uL of supernatant, and vacuum concentrate to dryness. Add 50uL of 50% methanol containing 5ng nimodipine to the residue for re-dissolution, vortex at 2500speed for 5min, ultrasonic at 100w for 10min, vortex again for 30s, centrifuge at 13000rpm for 10min, draw 40uL of supernatant, centrifuge at 13000rpm for 10min again, take 35uL of supernatant and transfer to the sample bottle for testing. The concentrations of standard samples for the final standard curve were 0.1, 0.2, 0.5, 1, 2, 5, 10, 20, 50, 100, 200, 500, and 1000 ng / mL.
[0286] Preparation and treatment of biological samples: Accurately draw 50μL of plasma to be tested, add 450μL of methanol and acetonitrile (1:1) precipitation solution, vortex at 2500speed for 5min, centrifuge at 13000rpm for 10min, draw 450uL of supernatant, and concentrate to dryness in vacuum. Add 50uL of 50% methanol solution containing 5ng nimodipine to the residue for re-dissolution, vortex at 2500speed for 5min, ultrasonic at 100w for 10min, vortex again for 30s, centrifuge at 13000rpm for 10min, draw 40uL of supernatant, centrifuge at 13000rpm for 10min again, take 35uL of supernatant and transfer to the sample bottle for testing.
[0287] Preparation and treatment of quality control samples: Prepare standard solutions containing the minimum quantitative limit, low, medium and high concentrations of ginsenoside Rh2. Accurately draw blank plasma and add the above standard solutions of different concentrations respectively, and treat them in the same way as above.
[0288] Chromatographic and mass spectrometric conditions: Chromatographic column XSelect HSS T3 C18 2.5μm, 2.1×100mm (Waters Co.). Mobile phase: A is acetonitrile / methanol (1:1 v / v) + 2mM ammonium acetate solution, B is water + 0.05% formic acid solution. Flow rate 0.2mL / min, sample cell temperature 10℃, injection volume 5μL. Negative ion scanning mode of electrospray ionization source (ESI).
[0289] Standard curve and linear range: The reference substance was prepared into a mixed reference substance solution of 1000 ng / mL, and then gradient dilution was performed to obtain a series of mixed reference substance solutions. 50 mL of blank rat plasma was placed in a centrifuge tube, and mixed reference substances and internal standard solutions of various concentrations were added respectively. After being processed according to the above biological sample processing method, LC-MS / MS analysis was performed, and the standard curve was drawn with the concentration as the horizontal axis (X) and the ratio of the peak area of each compound to the internal standard as the vertical axis (Y). The results showed that all compounds had a good linear relationship within the set concentration range. The regression equation of Rh2 is y=3.68377e-5x+2.95485e-4, the R2 value is 0.99906, and the linear range is 1-1000 ng / mL.
[0290] Precision: Take the above-mentioned quality control plasma samples of different concentrations, 5 copies for each concentration, analyze by HPLC-MS method, measure the concentration of the saponin component to be tested in each sample with the standard curve of the day, and measure continuously for three days. Calculate the intra-day precision and accuracy based on the measurement results within one day. Calculate the daily precision and accuracy based on the measurement results of three days. Precision is the degree of closeness of multiple measurement results, expressed as RSD (%), requiring the RSD of LQC to be less than or equal to 20%, and the RSD of the three quality control samples of low, medium and high to be less than or equal to 15%. Accuracy is the degree of closeness between the measured value and the true value (%), and the accuracy of biological sample determination is generally required to be between 85%-115%.
[0291] Take the quality control plasma samples of different concentrations from the merchant, 4 copies for each concentration, and prepare the mixed standard solution of the same concentration, 5 copies for each concentration, and analyze by LC-MS / MS method. The ratio of the peak area of Rh2, Rb1, Rg1, R1, Re, and Rd in the quality control sample to the corresponding peak area in the standard solution is used as the recovery rate, and the recovery rate of the biological sample is required to be between 80% and 120%.
[0292] Table 3 Intra-day (inter-day) precision and accuracy of LC-MS / MS for the detection of Rh2 in rat plasma
[0293]
[0294]
[0295] Stability: Take 50 μL of blank rat plasma and add three mass concentrations of reference solution to obtain three mass concentrations of ginsenoside Rh2 (QC). Freeze in a -40℃ refrigerator, then take out and thaw at room temperature, repeat freezing and thawing 3 times. After the last thawing at room temperature, process the plasma sample according to the method in 1.3 and perform LC-MS / MS determination.
[0296] Take 50 μL of blank rat plasma and add three mass concentrations of reference solution to obtain three mass concentrations of ginsenoside Rh2 (QC). Freeze at -40℃ for 15 days, thaw at room temperature, process the plasma samples according to method 1.3 and perform LC-MS / MS determination.
[0297] Take 50 μL of blank plasma from rats and add three mass concentrations of reference solution to obtain three mass concentrations of ginsenoside Rh2 (QC). Treat the plasma samples according to the method in 1.3 and place them at 4°C for 24 hours before LC-MS / MS determination. The results are shown in Table 3.
[0298] Table 4 LC-MS / MS detection of Rh2 in rat plasma under 4℃ conditions, long-term storage and repeated freeze-thaw cycles
[0299]
[0300] Recovery rate and matrix effect: Take the QC samples of the three mass concentrations of low, medium and high mentioned above, prepare 6 copies of each mass concentration in parallel, treat the plasma samples according to the method of 1.3 and perform LC-MS / MS determination, record the ratio of the peak area of the component to the peak area of the internal standard (A). Take another rat blank plasma, treat it according to the method under 4.2.1.3.1.2, then add the reference solution of three mass concentrations of low, medium and high, perform LC-MS / MS determination, record the ratio of the peak area of the component to the peak area of the internal standard (B), and calculate the extraction recovery rate according to the formula of extraction recovery rate = A / B×100%. Take another aqueous solution instead of blank plasma, treat the sample according to the method of 1.3 and perform LC-MS / MS determination, obtain the ratio of the peak area of the component to the peak area of the internal standard (C), and calculate the matrix effect according to the formula of matrix effect = A / C×100%.
[0301] Experimental Example 7 Experimental Method for Oral Bioavailability in Rats
[0302] Prepare blank SD rat plasma: fast for 24 hours (only normal drinking water, all bedding and feed are removed), anesthetize the rats, insert a cannula into the jugular vein to collect blood, collect blood into EDTA anticoagulant tubes, and centrifuge at 10°C, 3000rpm for 15min. Take the upper plasma, mix it, transfer it to a 2.0mL or 5.0ml EP tube, and store it at -80°C.
[0303] Rat jugular vein cannulation surgery: After fasting, SD rats were anesthetized by intraperitoneal injection of 7% chloral hydrate, and then jugular vein cannulation surgery was performed. After the surgery, the wound was sutured.
[0304] Dosage and grouping: The oral bioavailability study was divided into the following groups, with 8 mice in each group (n=8). After intubation, the mice were fasted for 18 hours and then gavage-administered. The following nanoformulation groups were all gavage-administered (dosage was 50 mg / kg):
[0305] ① Rh2 nanoparticles (Rh2-oleic acid-TPGS NPs, Example 3)
[0306] ②Rh2 suspension (suspended in 0.5% CMC-Na, ig)
[0307] ③ Borneol-containing Rh2 nanoparticles (Rh2-linoleic acid-borneol-TPGS NPs, Example 47)
[0308] Administration and sample collection: 0.3 mL of waste blood was drawn out before sampling. 0.4 mL of blood sample was drawn from a silicone tube using a 1 ml flat-head sampler and placed in a heparinized centrifuge tube at 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, and 24 h after administration. The blood sample was centrifuged at 5000 rpm for 10 min to separate the plasma and stored at -80 °C for testing.
[0309] Treatment of plasma samples: 50 μL of plasma to be tested was accurately drawn, 450 μL of methanol and acetonitrile (1:1) precipitation solution was added, vortexed at 2500 speed for 5 min, centrifuged at 13000 rpm for 10 min, 450 uL of supernatant was drawn, and vacuum concentrated to dryness. 50 uL of 50% methanol solution containing 5 ng nimodipine was added to the residue for reconstitution, vortexed at 2500 speed for 5 min, ultrasonicated at 100w for 10 min, vortexed again for 30 s, centrifuged at 13000 rpm for 10 min, 40 uL of supernatant was drawn, the supernatant was centrifuged at 13000 rpm for 10 min again, 35 uL of supernatant was transferred to a sample bottle, and the sample concentration was measured by UPLC-MS.
[0310] Results: To study the effect of Rh2 nanocomposite on the bioavailability of ginsenoside Rh2, oral administration of Rh2 aqueous suspension was selected as the control group. The pharmacokinetic parameters of rats are shown in Table 5. The Cmax of Rh2 nanocomposite group (Rh2NPs) and Rh2-borneol nanocomposite group (Rh2-borneol NPs) was significantly higher than that of Rh2 oral suspension control group. Compared with Rh2 aqueous suspension, Tmax of both experimental groups was delayed and mean residence time MRT was prolonged. The area under the drug-time curve (AUC) of Rh2 nanocomposite group (Rh2 NPs) and Rh2-borneol nanocomposite group (Rh2-borneol NPs) was 2.67 and 5.10 times that of Rh2 physical suspension, respectively, indicating that the nanocomposite significantly improved the oral bioavailability of ginsenoside Rh2, and the incorporation of borneol into nanoparticles could further improve the oral bioavailability of ginsenoside Rh2.
[0311] Table 5 Pharmacokinetic parameters of Rh2 in Rh2 nanoparticles (n=8)
[0312]
[0313] Note: Maximum blood drug concentration (peak concentration): Cmax; Time to peak: Tmax; Area under the curve: AUC0→∞; Mean residence time: MRTlast.
[0314] The above description of the disclosed embodiments enables one skilled in the art to implement or use the present invention. Various modifications to these embodiments will be apparent to one skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but rather to the widest scope consistent with the principles and novel features disclosed herein.
Claims
1. A ginsenoside Rh2 composition, characterized in that: The composition comprises ginsenoside Rh2, oleic acid / linoleic acid, and amphiphilic excipients; wherein, The weight ratio of ginsenoside Rh2, oleic acid / linoleic acid and amphiphilic excipient is 4:2-8:1-8.
2. The ginsenoside Rh2 composition according to claim 1, characterized in that: The composition comprises pharmaceutically acceptable excipients, wherein the excipients include excipients for adjusting osmotic pressure and pH, specifically glucose, sodium chloride, phosphate buffer, glycerol, and mannitol.
3. The ginsenoside Rh2 composition according to claim 1 or 2, characterized in that: The oleic acid / linoleic acid is a mixture of oleic acid and linoleic acid in any proportion, and the amphiphilic excipient includes one or more combinations of TPGS, PLA-PEG, PLGA-PEG, PCL-PEG, DSPE-PEG, phospholipids, and sodium oleate.
4. A method for preparing the ginsenoside Rh2 composition as claimed in claim 1, characterized in that: The method comprises the following steps: Ginsenoside Rh2, amphiphilic excipients, and oleic acid / linoleic acid are dissolved in an organic solvent to obtain a mixed solution; the mixed solution is added to water under stirring or ultrasound, and the organic solvent is removed by evaporation under reduced pressure to finally obtain the ginsenoside Rh2 composition.
5. A method for preparing the ginsenoside Rh2 composition as claimed in claim 1, characterized in that: The method comprises the following steps: Ginsenoside Rh2, oleic acid / linoleic acid, and amphiphilic excipients are dissolved in an organic solvent to obtain a mixed solution; the mixed solution is added to an aqueous solution containing sodium oleate under stirring or ultrasound, and the organic solvent is removed by evaporation under reduced pressure to finally obtain the ginsenoside Rh2 composition.
6. The method for preparing the ginsenoside Rh2 composition according to claim 4 or 5, characterized in that: The organic solvent includes one or more combinations of ethanol, methanol, and acetone. The volume of water is 3-50 times the volume of the organic solvent. The stirring speed is 300-2000 rpm. The water bath ultrasonic power is 100-500W.
7. The method for preparing the ginsenoside Rh2 composition according to claim 4 or 5, characterized in that: The water dispersion system prepared by the method is mixed with 1% mannitol and then freeze-dried to obtain the solid powder of the ginsenoside Rh2 composition.
8. Use of the ginsenoside Rh2 composition as claimed in claim 1 or the ginsenoside Rh2 composition prepared by the method as claimed in claim 4 or 5 in a pharmaceutical preparation.
Citation Information
Patent Citations
Nano emulsion of containing ginsenoside, preparation method and usage
CN1626104A
